NMPA-Approved Drug Library

Description: From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc.
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc.
MCE provides a unique collection of 1390 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
MCE NMPA-Approved Drug Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1355 compounds supplied in 10 mM solution, 22 compounds supplied in 2 mM solution and 13 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:

• A unique collection of 1390 approved compounds for high throughput screening (HTS) and high content screening (HCS).
• Used in the research of oncology, cardiology, anti-inflammatory, immunology, dermatology, endocrinology, neurology, and more.
• A useful tool for researching new targets of marketed old drugs.
• All compounds have been approved by the NMPA.
• Structurally diverse, bioactive, and cell permeable.
• More detailed compound information with structure, IC50, and brief introduction.
• NMR and HPLC validated ensure high purity.
• All compounds are in stock and continuously updated.

Formulation: A collection of 1390 NMPA approved compounds supplied as pre-dissolved Solutions or SolidSolution:1355 compounds supplied in 10 mM solution,22 compounds supplied in 2 mM solution,13 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

• Artikelnummer: MEXHY-L053-50
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-L053-50
• Green Labware: Nein
• Verpackungseinheit: 50 μl
• Mengeneinheit: STK